Research10 min read
Best GLP-1 for Women Over 40: What Actually Works
Hormonal shifts after 40 make weight loss harder. GLP-1 medications can help — but the research on women specifically tells a different story than the headlines.
Read more →PeptidePub Blog
Research findings, pricing news, and vendor analysis across the peptide market.
Posts about Semaglutide
Showing 1 to 7 of 7
Research9 min read
Do GLP-1 Drugs Raise or Lower Cancer Risk?
The current evidence does not show a broad human cancer-risk increase from GLP-1 drugs, and some studies suggest lower risk for obesity-related cancers. This explainer separates thyroid-label warnings, pancreatic-cancer fears, observational signals, and what the data cannot prove.
Read more →Research9 min read
Ozempic Shaming Is Real: What the New GLP-1 Stigma Research Shows
New studies show that people who lose weight with GLP-1 medications can be judged more harshly than people who lose weight through diet and exercise. Here is what the stigma research means for disclosure, care-seeking, and how we talk about obesity treatment.
Read more →Research10 min read
Do You Need to Diet and Exercise on GLP-1 Medications?
GLP-1s work without strict dieting — but the research shows that adding protein and resistance training dramatically improves results and prevents muscle loss.
Read more →Research9 min read
GLP-1 Medications for PCOS: What the Research Shows
PCOS affects 1 in 10 women and is driven by insulin resistance. GLP-1 medications target that root cause — and the early research is promising.
Read more →Research4 min read
Beyond Weight Loss: What New Research Reveals About GLP-1 Drugs
New research from the Technical University of Munich and Harvard Medical School reveals that semaglutide and tirzepatide don't just promote weight loss — they appear to fundamentally reshape the body's metabolic and inflammatory pathways in ways researchers didn't fully anticipate.
Read more →Research3 min read
Ozempic Linked to Reduced Depression, Anxiety, and Addiction Risk — What the New Data Shows
New research from the University of Eastern Finland has found that semaglutide (Ozempic/Wegovy) is associated with significantly reduced rates of depression, anxiety, and substance use disorders — adding to a growing body of evidence that GLP-1 drugs do far more than cause weight loss.
Read more →STOP PIECING IT TOGETHER
One article at a time is a slow way to learn peptides.
We wrote the shortcut: five books, 45 compounds, every claim graded by the strength of the real evidence. No hype, no gatekeeping, and free updates for life whenever the market shifts. Most readers say it replaces months of forum digging.
Get the Handbook30-day money-back guarantee. Free updates for life.